-
Vybion's Contract Biopharmaceutical Development includes early stage through Phase I/II.
Proprietary Technologies add value to biopharmaceutical product development.
Latest News
Vybion Awarded Monoclonal Antibody Development Contract. April 11, 2007
Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati. More
-
Protein Engineering Technology
ProCode™
- Human monoclonal antibody selection
- Affinity maturation simultaneously with selection
- Protein solubility optimization
- Molecule format engineering
- Complete development and process package
